Bentham Science Logo
Journal Cover

Current Pharmacogenomics

Continued as: Current Pharmacogenomics and Personalized Medicine

ISSN: 1570-1603 (Online)
ISSN: 1570-1603 (Print)
This journal supports open access

Aims & Scope

Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary, peer-reviewed, biomedical journal that reports new findings and cutting-edge concepts in all areas of pharmacology. Special consideration is given to articles on pharmacogenomics and personalized medicine. CPPM is an accelerator for global personalized medicine and pharmacogenomics, as well as preclinical and clinical pharmacology. Importantly, the journal provides a multi-disciplinary, integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries and the entire range of translational science from bench-to-bedside in various therapeutic areas such as oncology, cardiovascular, neuropharmacology, endocrine diseases, amongst others.

CPPM cooperates with the Ibero-American Network of Pharmacogenetics and the Pacific Rim Association for Clinical Pharmacogenetics and welcomes peer reviewed contributions from authors in any global region.

The journal's scope is defined by four inter-connected aims. First, we are interested in genomics/postgenomics biotechnologies and diagnostics that enable global personalized medicine science (including and beyond pharmacogenomics), as long as they explain person-to-person and population differences in disease susceptibility or response to a health intervention, and can be substantiated. Second, we approach personalized medicine as ‘personalized health interventions’ focusing primarily on drug therapy, but also other interventions such as nutrition, vaccines, surgical devices, emerging cell-based therapies that collectively contribute to healthcare. Third, we strive to integrate molecular and clinical investigation with public policy, global health diplomacy and social studies of biotechnology, that collectively shape postgenomics future(s) and innovation trajectories in life sciences. Fourth, we are interested in all aspects of translational pharmacology from preclinical to clinical applications in any therapeutic area that will advance the practice of medicine for the benefit of patients worldwide including non-communicable diseases as well as infectious diseases in the post- COVID world.

Priority will be given to expert reviews/ mini-reviews and research articles that include original ideas and findings related to the scope and mandate of the journal. Unsolicited submissions are welcomed.

Current Pharmacogenomics


Volume 5


Number 4

Connexin Genes as Promising Therapeutic Targets in Cancers

, 5(4): 314 - 318

Tomohiro Yano, Hiromi Sato, Hiromi Hagiwara and Nantiga Virgona

DOI: 10.2174/157016007782793737

Articles Ahead of Print

There are currently no Articles Ahead of Print available for this journal.

Abstracts Ahead of Print

There are currently no Abstracts Ahead of Print available for this journal.

Editor's Choice

Open Access Articles

About the Journal

For Librarians & Readers

Related Journals

Related eBooks

eBooks Catalog